Invictus MD (CNX:IMH) – Mr. Kveton is a highly effective, strategic and pragmatic international executive and investment professional, with broad experience operating in both Fortune 500 and start-up environments. He has a proven record in generating top-line growth by executing cross-border merger and acquisition deals and transformations to a high standard, and in developing new profit streams in regulated industries.
He is currently one of the founding partners of Logscale Venture Partners, a firm focused on early- and growth-stage companies in the health care space. Operating out of Switzerland, Mr. Kveton provides investors with early exposure to disruptive innovations/technologies in pharma, medtech, biotechnology and life science, and in the adjacent fields of personalized medicine, diagnostics and e-health. He has in-depth strategic and corporate development experience of the fast-moving consumer goods and has had extensive involvement with leading consultancy companies.
With over 20 years of deal-making experience, Mr. Kveton has worked for leading tobacco players. As vice-president, business development, at Japan Tobacco International (JTI) he led several M&A transactions valued at $1.5-million (U.S.), and was appointed by the chief executive officer to expand JTI’s presence in the United States and Latin America, with parallel responsibility for deal origination and execution in the area of emerging products. Formerly while at Philip Morris International, he led two major acquisitions (up to $1-billion (U.S.)), readied businesses in Poland, Hungary, Czech and Slovak Republics for European Union accession, and facilitated new market entries into Croatia and neighbouring countries. His multibillion-dollar private and public company deal sheet is global, spanning five continents.
A graduate of Queen’s University in Canada, and executive programs at U.C. Berkeley Haas School of Business and Harvard Business School, Mr. Kveton is an active angel investor and a true partner to entrepreneurs, bringing stewardship and management depth to their businesses.
“George is an outstanding addition to the board, bringing extensive global business development, finance and acquisition experience, and further enhancing our board,” said Dan Kriznic, chairman and chief executive officer. “His international network and reputation, along with his valuable knowledge and sound judgment, will serve the company and our shareholders well, as we continue on our journey of rapid growth, which includes expanding our production capacity and further establishing our leadership position as Canada’s cannabis company.”
“I am delighted to join Invictus MD and to become part of this truly dynamic team that will continue to provide leadership in the burgeoning cannabis sector,” said Mr. Kveton. “This company has captivated me in terms of its rapid growth, management and board strength, disciplined execution of its strategic plan, and vision for the future of the industry. I look forward to contributing to Invictus MD’s strategic decision making.”
About Invictus MD Strategies Corp.
Invictus MD Strategies is focused on three main verticals within the burgeoning Canadian cannabis sector: licensed producers under the cannabis for medical purposes regulations (ACMPR); fertilizer and nutrients through Future Harvest Development Ltd.; and cannabis data and delivery, with its wholly owned subsidiary Poda Technologies Ltd.
Click here to connect with Invictus MD (CNX:IMH) to receive an Investor Presentation.

PharmaTher Inc., a wholly-owned subsidiary of Newscope Capital Corporation (“PharmaTher”) (CSE: PHRM) and a specialty life sciences company focused on the research and development of psychedelic pharmaceuticals, is pleased to provide a corporate update on its psychedelic pharmaceuticals program. Since its inception, the Company has built a unique product pipeline for novel uses of ketamine, psilocybin and undisclosed psychedelics. PharmaTher is positioning itself to partner its psilocybin program and panaceAI™, and focus on advancing its novel ketamine product pipeline in Parkinson’s disease, depression and pain via the U.S. Food and Drug Administration (“FDA”) regulatory pathway.

“We have made tremendous progress over the last several months that saw our product pipeline evolve to focus on the massive opportunity and potential of ketamine, an FDA approved drug with a known safety profile, to treat significant unmet medical needs for Parkinson’s disease, depression and pain,” said Fabio Chianelli, CEO of PharmaTher. “With our focus on ketamine through repurposing, combining it with an FDA approved drug and delivering it with our novel microneedle delivery system, we are now positioned to expedite our clinical development objectives by taking advantage of the FDA’s 505(b)(2) regulatory pathway and commercializing disruptive ketamine treatments for mental health and pain disorders.”

Keep reading... Show less

Wall Street Reporter, the trusted name in financial news since 1843, has published reports on the latest comments and insights from leaders at: Tilray, Inc. (NASDAQ: TLRY), Icanic Brands (OTC: ICNAF) (CSE: ICAN), Aurora Cannabis (NYSE: ACB)(TSX: ACB), and Canopy Growth Corporation (NASDAQ: CGC) (TSX: WEED).

Cannabis leaders are focusing on innovation in premium branding, global expansion, and tight operational execution in the drive towards profitability. Wall Street Reporter highlights the latest comments from industry thought leaders:

Keep reading... Show less

Chemesis International Inc. (the “Company”) (CSE:CSI)(OTCQB:CADMF)(FRA:CWAA

The Company announces that its (former) subsidiary, Natural Ventures PR, LLC (“NVPR”), has sold all of its cannabis assets, and assigned all related liabilities, licenses and permits, to Puerto Rico Industrial Commercial Holdings Biotech Corp. (“PRICH”) in exchange for immediate net cash proceeds to the Company, in respect of its 80% interest in NVRP, of US$450,000. The Company notes that, in connection with, and as a condition to, this transaction, it will cease to be a shareholder of NVPR.

Keep reading... Show less

Progressive Planet Solutions Inc. (TSXV: PLAN) (“PLAN” or “Progressive Planet”), an emerging leader in reducing the carbon footprint of cement products using natural pozzolans, is pleased to announce it has sold and optioned a combined total of 10 million of its 10.5 million shares of Snow Lake Resources.

The sale and option agreements were made with two arms-length purchasers. The first sale was for 1,700,000 shares at $0.04 per share for a total of $68,000 and includes an option granted by PLAN entitling the same party to purchase an additional 4,966,666 shares at $0.04 per share until May 11, 2021 . The second sale was for 1,250,000 shares at $0.04 per share for a total of $50,000 and includes an option granted by PLAN to such party to purchase an additional 2,083,334 shares until August 14, 2021 . As at the date of this news release, PLAN has received $116,000 and will receive another $284,000 if the remaining shares are purchased under the option agreements.

Keep reading... Show less

First Products to Hit California Shelves in Q2 2021

 4Front Ventures Corp. (CSE: FFNT) (OTCQX: FFNTF) (” 4Front ” or the ” Company “) is pleased to announce that its fully funded state of the art 185,000 square foot production facility in Commerce, California is nearing completion and will be ready to serve the $3b California cannabis market in Q2 2021. The project is on target to be completed in April 2021 with the Company planning for the first of its full line of edibles, tinctures and vape products to be on California retail shelves by May.

Keep reading... Show less